Welcome to our dedicated page for Regeneron Pharmaceuticals news (Ticker: REGN), a resource for investors and traders seeking the latest updates and insights on Regeneron Pharmaceuticals stock.
Regeneron Pharmaceuticals (NASDAQ: REGN) is a leading biotechnology innovator developing transformative treatments for serious diseases through advanced platforms like VelociSuite®. This page serves as the definitive source for official company announcements, research milestones, and therapeutic developments.
Investors and medical professionals will find curated updates including FDA approvals, clinical trial results, partnership announcements, and financial reports. Our aggregation ensures timely access to Regeneron's progress in oncology, immunology, rare diseases, and ophthalmic therapies.
All content is sourced directly from Regeneron's communications and verified financial disclosures. Bookmark this page to monitor the company's pipeline advancements, regulatory updates, and strategic collaborations that drive biopharmaceutical innovation.
Regeneron Pharmaceuticals and Sanofi announced that Dupixent (dupilumab) successfully met its primary and key secondary endpoints in a Phase 3 trial for children aged 6-11 with uncontrolled moderate-to-severe asthma. The study showed Dupixent reduced severe asthma attacks by up to 65% and improved lung function significantly within two weeks. Regulatory submissions in the U.S. and EU for this age group are anticipated by Q1 2021. The safety profile was consistent with previous findings, showing Dupixent as a promising option for children suffering from this serious condition.
Regeneron Pharmaceuticals (NASDAQ: REGN) will report its third quarter 2020 financial results on November 5, 2020, before the U.S. markets open. A conference call and webcast will be held at 8:30 AM ET on the same day. To participate, dial (888) 660-6127 (U.S.) or (973) 890-8355 (International) with conference ID 1535889. Regeneron is known for developing life-transforming medicines and has seven FDA-approved treatments. Its innovative technologies, like VelociSuite, enhance drug development processes.
On September 29, 2020, Regeneron Pharmaceuticals announced promising results from a Phase 1/2/3 trial of REGN-COV2, its investigational antibody cocktail for COVID-19. The study showed significant reductions in viral load and symptom duration among non-hospitalized patients, particularly those without effective immune responses. Results indicated faster symptom alleviation and a favorable safety profile; both high and low doses of REGN-COV2 were well-tolerated. Regeneron plans to discuss these findings with regulatory agencies and host a webcast for investors.
Regeneron Pharmaceuticals and Sanofi presented positive data from a pivotal trial of Libtayo (cemiplimab) for first-line treatment of advanced non-small cell lung cancer (NSCLC) at the ESMO Virtual Congress 2020. Libtayo demonstrated a 32% reduction in risk of death compared to chemotherapy, with a median overall survival of 22 months versus 14 months for chemotherapy. In patients with PD-L1 expression ≥50%, Libtayo showed a 43% reduction in death risk. The drug is being developed under a global collaboration agreement.
Regeneron Pharmaceuticals and Sanofi announced promising results from the Phase 2 trial of Libtayo® (cemiplimab) for advanced basal cell carcinoma (BCC) after hedgehog inhibitor therapy. The trial, presented at the ESMO Virtual Congress 2020, reported a 31% objective response rate (ORR) with 85% of responses ongoing at one year. Key findings include a median follow-up of 15 months, with a probability of overall survival at 92%. No new safety signals were observed, though 17% of patients discontinued treatment due to adverse events. Libtayo is still under investigation for this indication.
Regeneron Pharmaceuticals and the University of Oxford announced the RECOVERY trial to evaluate the investigational COVID-19 treatment REGN-COV2. This Phase 3 trial will compare the addition of REGN-COV2 to the standard care in COVID-19 hospitalized patients, assessing its impact on mortality and hospital stays. The trial aims to include at least 4,000 participants across 176 UK hospitals. The success of REGN-COV2 could provide significant insights into effective treatment options for COVID-19, complementing existing therapies like dexamethasone.
Regeneron Pharmaceuticals and Sanofi announced that the FDA granted Breakthrough Therapy designation to Dupixent for treating eosinophilic esophagitis (EoE) in patients 12 and older. This designation follows positive results from a Phase 3 trial, where Dupixent met its primary and secondary endpoints, showcasing significant symptom reduction and improved esophageal health. With approximately 160,000 patients in the U.S. affected by EoE and no FDA-approved treatments, this designation highlights Dupixent's potential as a first-in-class therapy for this chronic condition.
Regeneron Pharmaceuticals and Sanofi announced results from a Phase 3 open-label extension trial for Dupixent, the largest study of a biologic in asthma with over 2,200 patients. Results indicate sustained improvements in lung function and reduced severe asthma attacks over three years. The average change in FEV1 was 13-22%, with low rates of severe attacks averaging 0.31-0.35 events per year. Safety profiles showed AE rates consistent with previous trials. The data emphasizes Dupixent's role as a long-term treatment option for patients suffering from moderate-to-severe asthma.
Sanofi and Regeneron Pharmaceuticals (NASDAQ: REGN) will present promising data for Libtayo® (cemiplimab) at the ESMO Virtual Congress 2020 from September 19-21. Key highlights include late-breaking oral presentations on Libtayo monotherapy for first-line advanced non-small cell lung cancer (NSCLC) and advanced basal cell carcinoma (BCC) post-hedgehog inhibitor treatment. The clinical trials demonstrate Libtayo's effectiveness across various cancers, which may support regulatory submissions in the U.S. and EU. Additional presentations will focus on patient quality of life and treatment demographics.
Regeneron Pharmaceuticals and Sanofi presented promising new data for Libtayo® (cemiplimab) at the ESMO Virtual Congress 2020. Key highlights include late-breaking oral presentations on Libtayo's efficacy as a monotherapy for first-line advanced non-small cell lung cancer (NSCLC) and locally advanced basal cell carcinoma (BCC) in patients resistant to hedgehog inhibitors. The trials show Libtayo's potential to improve treatment outcomes in challenging cancers, supporting regulatory submissions in the U.S. and EU.
